Galantamine

Generic Name
Galantamine
Brand Names
Razadyne
Drug Type
Small Molecule
Chemical Formula
C17H21NO3
CAS Number
357-70-0
Unique Ingredient Identifier
0D3Q044KCA
Background

Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as Galanthus nivalis. Galantam...

Indication

Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.

Associated Conditions
Mild to Moderate Dementia Due to Alzheimer's Disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia
Associated Therapies
-
Clinical Trials
Related News

Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans

Phase 1
Recruiting
Conditions
Endothelial Dysfunction
Interventions
Drug: Placebo
Drug: Galantamine
First Posted Date
2021-02-24
Last Posted Date
2024-04-12
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
88
Registration Number
NCT04769206
Locations
🇺🇸

Chaney Johnson, Nashville, Tennessee, United States

Effect of Galantamine on Inflammation and Cognition

First Posted Date
2017-12-27
Last Posted Date
2024-10-17
Lead Sponsor
University of Pennsylvania
Target Recruit Count
63
Registration Number
NCT03384784
Locations
🇺🇸

Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study

First Posted Date
2017-01-09
Last Posted Date
2018-08-13
Lead Sponsor
Vanderbilt University Medical Center
Registration Number
NCT03014323
Locations
🇺🇸

Cyndya Shibao, Nashville, Tennessee, United States

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Racial Differences in Vagal Control of Glucose Homeostasis

First Posted Date
2015-02-18
Last Posted Date
2019-03-19
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
23
Registration Number
NCT02365285
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Galantamine Effects in Patients With Metabolic Syndrome

First Posted Date
2014-11-05
Last Posted Date
2017-02-15
Lead Sponsor
University of Sao Paulo
Target Recruit Count
60
Registration Number
NCT02283242
Locations
🇧🇷

University of São Paulo, Heart Institute, Medical School, São Paulo, Brazil

Symptomatic Treatment of Vascular Cognitive Impairment

First Posted Date
2014-03-28
Last Posted Date
2016-05-02
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
30
Registration Number
NCT02098824
Locations
🇳🇱

VU University Medical Center, Amsterdam, Netherlands

A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease

Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Galantamine
First Posted Date
2012-11-27
Last Posted Date
2013-08-05
Lead Sponsor
Janssen Korea, Ltd., Korea
Target Recruit Count
1882
Registration Number
NCT01734395

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

First Posted Date
2012-09-03
Last Posted Date
2017-05-30
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
542
Registration Number
NCT01677754
Locations
🇺🇸

Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States

🇨🇦

Vancouver Island Health Authority, Victoria, British Columbia, Canada

🇺🇸

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States

and more 139 locations

Effect of Galantamine on Short-term Abstinence

Phase 2
Completed
Conditions
Tobacco Use Disorder
Interventions
Drug: Placebo
Drug: Galantamine
First Posted Date
2012-08-21
Last Posted Date
2019-02-15
Lead Sponsor
University of Pennsylvania
Target Recruit Count
98
Registration Number
NCT01669538
Locations
🇺🇸

Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy